The drug treats complicated skin and skin structure infections caused by certain bacteria.Drug maker Schering-Plough (NYSE: SGP) in Kenilworth said the Food and Drug Administration (FDA) has approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback